

## Monoclonal Antibodies for COVID 19 FAX orders to 540-636-0345 (WMH only)

ALLERGIES				
Weight in Kilograms Height				
DIAGNOSIS: COVID-19 STATUS: OUTPATIENT HCPCS Codes: Q0222 (drug), M0222 (admin)				
Emergency Use Authorization				
For non-hospitalized patients, not on oxygen or without an increase in home oxygen flow rate				
***FORM MUST BE COMPLETED IN ENTIRETY OR ORDER WILL BE REJECTED***				
1. POSITIVE SARS-CoV-2 test:  VES  NO DATE:				
1. POSITIVE SARS-COV-2 test.       1. POSITIVE SARS-COV-2 test.         2. DATE OF SYMPTOM ONSET (Must be within 7 days):				
3. ***REASON for NOT prescribing 1st line drug nirmatrelvir/ritonavir (Paxlovid):				
<ul> <li>ABSOLUTE drug interaction contraindication List drug(s):</li> <li>eGFR less than 30 ml/min (Including dialysis patients)</li> </ul>				
<ul> <li>4. Vaccination Status: □ 2-Dose Pfizer or Moderna □ J&amp;J □ Booster/3<sup>rd/4<sup>th</sup></sup> dose □ Unvaccinated</li> <li>5. Code Status: □ Full Code or □ No CPR – Support OK □ No CPR – Allow Natural Death</li> </ul>				
••				
6. High Risk Criteria (Please check all that apply):				
Body mass index (BMI) greater or equal to 30 BMI:				
Chronic kidney disease, stages 3 to 5				
□ Diabetes				
<ul> <li>Currently receiving immunosuppressant treatment         – chemotherapy, immunotherapy, prednisone</li> <li>20 mg daily or equivalent, OR have chronic immunosuppressive disease</li> </ul>				
□ Age 65 years or greater				
<ul> <li>Cardiovascular disease or hypertension</li> </ul>				
Chronic lung disease				
□ Sickle cell disease				
<ul> <li>Neuro-developmental disorders (ex. Cerebral palsy)</li> </ul>				
Pregnancy: Weeks:				
Date: Time: Physician Phone Number:				
Physician Signature:				
Physician Name (Print):				



Warren Memorial Hospital

## Monoclonal Antibodies for COVID 19 FAX orders to 540-636-0345 (WMH only)

ALLERGIES				
Weight in Kilograms Height				
DIAGNOSIS: COVID-19		STATUS:	OUTPATIENT	
• •		ody medication/route bas	ed on availability or variants ringe extension set	
Obtain vital signs prior t	o the injection/in	fusion and at the end of	the injection/infusion	
• <b>Monitor</b> the patient for any signs of an <b>anaphylactic reaction</b> . Stop the injection/infusion if any of the following occur: Fever, chills, nausea, headache, bronchospasm, hypotension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, or dizziness				
Monitor the patient for one hour after the end of the injection/infusion				
For allergic/anaphylactic	reactions			
<ul> <li>Stop the injection/infusion and notify the MERT team</li> </ul>				
<ul> <li>Epinephrine 0.3 mg (1mg/ml) IM x 1 dose as needed for anaphylaxis (see above anaphylactic reaction signs)</li> </ul>				
<ul> <li>Diphenhydramine (Benadryl) 25 mg IV or PO X 1 dose for itching, swelling, or rash</li> </ul>				
<ul> <li>Famotidine (Pepcid) 40 mg IV x 1 dose for itching, swelling, or rash</li> </ul>				
Methylprednisolone (Solu-Medrol) 125 mg IV x 1 dose for itching, swelling, or rash				
Albuterol sulfate (Proventil) 2 puffs inhaled every 10 minutes up to 3 doses for wheezing, bronchospasm				
If a reaction occurs, document in EPIC, complete risk report, and notify pharmacy				
7.				
Provider to Complete:				
8.  Risks and benefits of the second	8.  □ Risks and benefits discussed with patient and obtain informed consent			
9. Department Information Sheet provided to patient/caregiver				
Date:	Time:	Physician Phon	e Number:	
Physician Signature:				
Physician Name (Print):				